查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1538449

前列腺癌抗原 3 檢測市場報告：2030 年趨勢、預測與競爭分析

Prostate Cancer Antigen 3 Test Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

前列腺癌抗原 3 檢測的趨勢和預測

預計 2024 年至 2030 年，全球前列腺癌抗原 3 檢測市場將以 7.7% 的複合年成長率成長。該市場的主要促進因素是全球前列腺癌發病率不斷上升、意識和早期篩檢計劃的提高以及對非侵入性和準確診斷工具的需求不斷成長。全球前列腺癌抗原 3 檢測市場的未來前景廣闊，醫院和專科診所市場充滿機會。

前列腺癌抗原3檢測按細分市場預測

本研究按類型、應用和地區對全球前列腺癌抗原 3 測試市場進行了預測。

前列腺癌抗原 3 測試市場洞察

Lucintel 預測 RT-PCR 將經歷最高的成長。

在這個市場中，醫院預計將呈現更高的成長。

亞太地區預計成長最快。

常問問題

Q1.市場成長預測是多少：

A1. 2024年至2030年，全球前列腺癌抗原3檢測市場預計將以7.7%的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 該市場的主要驅動力是全球前列腺癌發病率不斷上升、意識和早期篩檢計劃的提高以及對非侵入性和準確診斷工具的需求不斷成長。

Q3.市場的主要細分市場是：

A3. 前列腺癌抗原3檢測市場前景廣闊，醫院和專科診所市場充滿機會。

Q4.市場的主要企業是：

A4. 攝護腺癌抗原3檢測的主要企業如下：

  • Mdxhealth
  • Myriad Genetics
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens
  • OPKO Health
  • Genomic Health
  • BD
  • Agilent Technologies
  • Danaher

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預測 RT-PCR 將經歷最高的成長。

Q6.未來五年預計哪些地區的市場成長最大？

A6.亞太地區預計成長最快。

Q7. 可以客製化報告嗎？

A7。

目錄

第1章執行摘要

第2章全球前列腺癌抗原3檢測市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球前列腺癌抗原3檢測市場趨勢（2018-2023）與預測（2024-2030）
  • 全球前列腺癌抗原3檢測市場（按類型）
    • RT-PCR
    • 酵素連結免疫吸附試驗
    • 微量中和測定
  • 按應用分列的前列腺癌抗原 3 測試的全球市場
    • 醫院
    • 專科診所
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 按地區分類的前列腺癌抗原 3 測試的全球市場
  • 北美前列腺癌抗原3檢測市場
  • 歐洲前列腺癌抗原3檢測市場
  • 亞太地區前列腺癌抗原3檢測市場
  • 其他地區前列腺癌抗原3檢測市場

第5章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球前列腺癌抗原 3 檢測市場按類型分類的成長機會
    • 全球前列腺癌抗原 3 檢測市場成長機會（按應用）
    • 全球前列腺癌抗原 3 檢測市場成長機會（按地區）
  • 全球前列腺癌抗原3檢測市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球前列腺癌抗原3檢測市場產能
    • 全球前列腺癌抗原3檢測市場的合併、收購與合資
    • 認證和許可

第7章主要企業概況

  • Mdxhealth
  • Myriad Genetics
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens
  • OPKO Health
  • Genomic Health
  • BD
  • Agilent Technologies
  • Danaher
簡介目錄

Prostate Cancer Antigen 3 Test Trends and Forecast

The future of the global prostate cancer antigen 3 test market looks promising with opportunities in the hospital and specialist clinic markets. The global prostate cancer antigen 3 test market is expected to grow with a CAGR of 7.7% from 2024 to 2030. The major drivers for this market are growing incidence of prostate cancer globally, increasing awareness & early screening programs, and rising demand for non-invasive & accurate diagnostic tools.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Prostate Cancer Antigen 3 Test by Segment

The study includes a forecast for the global prostate cancer antigen 3 test by type, application, and region.

Prostate Cancer Antigen 3 Test Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • RT-PCR
  • ELISA Test
  • Micro-Neutralization Assays

Prostate Cancer Antigen 3 Test Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital
  • Specialist Clinic
  • Others

Prostate Cancer Antigen 3 Test Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Prostate Cancer Antigen 3 Test Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies prostate cancer antigen 3 test companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the prostate cancer antigen 3 test companies profiled in this report include-

  • Mdxhealth
  • Myriad Genetics
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens
  • OPKO Health
  • Genomic Health
  • BD
  • Agilent Technologies
  • Danaher

Prostate Cancer Antigen 3 Test Market Insights

Lucintel forecasts that RT-PCR is expected to witness the highest growth.

Within this market, hospital is expected to witness higher growth.

APAC is expected to witness the highest growth.

Features of the Global Prostate Cancer Antigen 3 Test Market

Market Size Estimates: Prostate cancer antigen 3 test market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Prostate cancer antigen 3 test market size by type, application, and region in terms of value ($B).

Regional Analysis: Prostate cancer antigen 3 test market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the prostate cancer antigen 3 test market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the prostate cancer antigen 3 test market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for prostate cancer antigen 3 test market?

Answer: The global prostate cancer antigen 3 test market is expected to grow with a CAGR of 7.7% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the prostate cancer antigen 3 test market?

Answer: The major drivers for this market are growing incidence of prostate cancer globally, increasing awareness & early screening programs, and rising demand for non-invasive & accurate diagnostic tools.

Q3. What are the major segments for prostate cancer antigen 3 test market?

Answer: The future of the prostate cancer antigen 3 test market looks promising with opportunities in the hospital and specialist clinic markets.

Q4. Who are the key prostate cancer antigen 3 test market companies?

Answer: Some of the key prostate cancer antigen 3 test companies are as follows:

  • Mdxhealth
  • Myriad Genetics
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Siemens
  • OPKO Health
  • Genomic Health
  • BD
  • Agilent Technologies
  • Danaher

Q5. Which prostate cancer antigen 3 test market segment will be the largest in future?

Answer: Lucintel forecasts that RT-PCR is expected to witness the highest growth.

Q6. In prostate cancer antigen 3 test market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness the highest growth.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the prostate cancer antigen 3 test market by type (RT-PCR, ELISA test, and micro-neutralization assays), application (hospital, specialist clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Prostate Cancer Antigen 3 Test Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Prostate Cancer Antigen 3 Test Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Prostate Cancer Antigen 3 Test Market by Type
    • 3.3.1: RT-PCR
    • 3.3.2: ELISA Test
    • 3.3.3: Micro-Neutralization Assays
  • 3.4: Global Prostate Cancer Antigen 3 Test Market by Application
    • 3.4.1: Hospital
    • 3.4.2: Specialist Clinic
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Prostate Cancer Antigen 3 Test Market by Region
  • 4.2: North American Prostate Cancer Antigen 3 Test Market
    • 4.2.1: North American Prostate Cancer Antigen 3 Test Market by Type: RT-PCR, ELISA Test, and Micro-Neutralization Assays
    • 4.2.2: North American Prostate Cancer Antigen 3 Test Market by Application: Hospital, Specialist Clinic, and Others
  • 4.3: European Prostate Cancer Antigen 3 Test Market
    • 4.3.1: European Prostate Cancer Antigen 3 Test Market by Type: RT-PCR, ELISA Test, and Micro-Neutralization Assays
    • 4.3.2: European Prostate Cancer Antigen 3 Test Market by Application: Hospital, Specialist Clinic, and Others
  • 4.4: APAC Prostate Cancer Antigen 3 Test Market
    • 4.4.1: APAC Prostate Cancer Antigen 3 Test Market by Type: RT-PCR, ELISA Test, and Micro-Neutralization Assays
    • 4.4.2: APAC Prostate Cancer Antigen 3 Test Market by Application: Hospital, Specialist Clinic, and Others
  • 4.5: ROW Prostate Cancer Antigen 3 Test Market
    • 4.5.1: ROW Prostate Cancer Antigen 3 Test Market by Type: RT-PCR, ELISA Test, and Micro-Neutralization Assays
    • 4.5.2: ROW Prostate Cancer Antigen 3 Test Market by Application: Hospital, Specialist Clinic, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Prostate Cancer Antigen 3 Test Market by Type
    • 6.1.2: Growth Opportunities for the Global Prostate Cancer Antigen 3 Test Market by Application
    • 6.1.3: Growth Opportunities for the Global Prostate Cancer Antigen 3 Test Market by Region
  • 6.2: Emerging Trends in the Global Prostate Cancer Antigen 3 Test Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Prostate Cancer Antigen 3 Test Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Prostate Cancer Antigen 3 Test Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Mdxhealth
  • 7.2: Myriad Genetics
  • 7.3: Abbott
  • 7.4: F. Hoffmann-La Roche Ltd
  • 7.5: Siemens
  • 7.6: OPKO Health
  • 7.7: Genomic Health
  • 7.8: BD
  • 7.9: Agilent Technologies
  • 7.10: Danaher